Doopyo Hong
Overview
Explore the profile of Doopyo Hong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoo Y, Park S, Jo E, Choi M, Lee K, Hong D, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34206586
Liposarcoma (LPS) is an adult soft tissue malignancy that arises from fat tissue, where well-differentiated (WD) and dedifferentiated (DD) forms are the most common. DDLPS represents the progression of WDLPS...
2.
Jo E, Lee H, Lee K, Kim S, Hong D, Park J
Am J Transl Res
. 2020 Aug;
12(7):3993-4000.
PMID: 32774752
De-differentiated liposarcoma (DDLPS) is a rare cancer with high rates of recurrence and metastasis. Currently, treatment with doxorubicin-ifosphamide, following surgical resection, is routinely performed. However, clinical treatment of these refractory...
3.
Choi B, Lee J, Kim S, Hong D, Park J, Lee K
Cancer Lett
. 2020 Mar;
478:56-69.
PMID: 32145342
The efficacy of an immune checkpoint blockade has been demonstrated against various types of cancer, but its suitability has not been fully proven for therapies specifically targeting sarcoma. We conducted...
4.
Jo E, Lee Y, Lee H, Park J, Park H, Choi Y, et al.
BMC Cancer
. 2019 May;
19(1):496.
PMID: 31126284
Background: Liposarcoma (LPS) is a tumor derived from adipose tissue, and has the highest incidence among soft tissue sarcomas. Dedifferentiated liposarcoma (DDLPS) is a malignant tumor with poor prognosis. Recurrence...
5.
Jo E, Hong D, Lee Y, Lee H, Park J, Kim S
Transl Oncol
. 2018 Nov;
12(2):269-281.
PMID: 30447641
The patient-derived xenograft (PDX) model has been adopted as a major tool for studying tumorigenesis and differentiation in various carcinomas. In addition, it has been used in the development of...
6.
Nam S, Kim H, Hong D, Park J, Kim S
Anticancer Res
. 2017 Oct;
37(11):6291-6302.
PMID: 29061812
Background/aim: Heat shock protein 90 (HSP90) inhibitors have recently been tested as anticancer drugs in a variety of carcinomas. Yet, there exist only few reports about HSP90 inhibitor and its...
7.
Lee H, Jo E, Kim S, Yang H, Kim Y, Sung Y, et al.
Cytotherapy
. 2017 Aug;
19(9):1035-1047.
PMID: 28760351
Background Aims: Major challenges in de-differentiated liposarcoma (DDLPS) therapy are the high rate of sequential recurrence (>80%) and metastasis (20-30%) following surgical removal. However, well-defined therapeutic strategies for this rare...
8.
Zhang Z, Hong D, Nam S, Kim J, Paik Y, Joh J, et al.
J Hepatol
. 2014 Aug;
62(1):121-30.
PMID: 25131770
Background & Aims: SIRT1 is a class III histone deacetylase that plays diverse roles in various cancers. However, the clinical significance of SIRT1 in hepatocellular carcinoma (HCC) remains unknown. Methods:...
9.
Shin M, Hong D, Zhang Z, Kim Y, Lee W, Joh J, et al.
HPB (Oxford)
. 2013 Mar;
15(12):965-75.
PMID: 23496059
Background: Erythropoietin, through its specific receptor (EpoR), may induce responses in a variety of non-haematopoietic tissues including malignant cells. The purpose of this study was to examine the expression of...